A day earlier, its shares surged as much as 48% to a record high after Vaxcyte said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety profile similar to Pfizer's Prevnar 20 shot.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/kYKzZab
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment